Dr. Haddad wants to be a translational scientist focusing on utilizing genetics to personalize medicine. He hopes to develop novel methods and approaches to improve translation of genetic data into clinical outcomes for patients. His current research utilizes diverse biobank cohorts to improve pharmacogenomic testing in underrepresented populations.
Education & Training
- BS (Biochemistry & Molecular Biology), University of California Davis, 2016
- PharmD, University of Pittsburgh School of Pharmacy, 2021
- PhD (Pharmaceutical Sciences), University of Pittsburgh School of Pharmacy, Expected 2025
Representative Publications
Haddad A, Radhakrishnan A, McGee S, Smith J, Karnes J, Venner E, Wheeler M, Patterson K, Walker K, Kalra D, Kalla S, Wang Q, Gibbs R, Jarvik G, Sanchez J, Musick A, Ramirez A, Denny J, Empey P, on behalf of the All of Us Research Program Investigators. Frequency of pharmacogenomic variation and medication exposures among All of Us Participants. medRxiv. 2024.
Venner E, Patterson K, Kalra D, Wheeler MM, Chen YJ, Kalla SE, Yuan B, Karnes JH, Walker K, Smith JD, McGee S, Radhakrishnan A, Haddad A, Empey PE, Wang Q, Lichtenstein L, Toledo D, Jarvik G, Musick A, Gibbs RA; All of Us Research Program Investigators. The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities. Commun Biol. 2024 Feb 19;7(1):174.
Turner AJ, Haider CE, Yang W, Boone EC, Offer SM, Empey PE, Haddad A, Tahir S, Scharer G, Broeckel U, Gaedigk A. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci. 2024 Jan;17(1):e13699.
Research Interests
- Genomics
- Bioinformatics